Christine Lind assumed the function of CEO of Bactiguard AB on April 12, 2024, in keeping with the corporate’s board.
Bactiguard manufactures of airway administration merchandise, together with the BIP Endotracheal Tube and the BIP Endotracheal Tube Evac, which function a beveled tip, Murphy Eye, excessive volume-low strain cuff, and subglottic secretion drainage.
“It feels implausible having Christine assuming the function as our new CEO already immediately. Bactiguard has sharpened its technique and carried out robust however crucial modifications within the work in the direction of changing into a specialist and information group. Christine’s expertise of driving change and strategic shifts can be central as we now take the following step on Bactiguard’s growth, each a business shift and for the company tradition. Her worldwide profile is essential on condition that Bactiguard’s important stakeholders are world MedTech firms”, says Christian Kinch, Chairman of the Board of Bactiguard.
“Throughout a few weeks, I’ve had the possibility to get to know Bactiguard higher and I see nice potential in each the group and the distinctive an infection prevention know-how. With a concentrate on license companions, we get entry to the worldwide MedTech market and might scale up the enterprise in an economical method. On the identical time, we will shield extra sufferers and, along with our license companions, improve our optimistic influence. And never least, make Bactiguard worthwhile and create sustainable progress for the corporate. I sit up for working along with the board and workforce at Bactiguard on our essential function to make the world more healthy by stopping infections,” says Christine Lind, CEO of Bactiguard.
Thomas von Koch, Board Member and interim CEO feedback: “It has been thrilling to steer Bactiguard and get to know the group on an operational degree. As I mentioned after I took over final summer season, the license enterprise has the best progress potential. With the brand new license-focused technique, we’re properly on our method to changing into a full-scale world MedTech firm with a concentrate on partnerships. It’s with nice confidence that I hand over the CEO function to Christine and sit up for a continued rewarding collaboration. I’d additionally wish to thank all my devoted colleagues at Bactiguard for a implausible collaboration throughout my greater than ten months as CEO.”
Christine Lind has broad expertise, each strategic and operational, from greater than 25 years within the healthcare sector. Born in 1974 within the US and residing in Sweden since 2015, she holds a BSc in Finance & Info Techniques from New York College and an MBA from Columbia Enterprise College. Throughout her profession, she has held CEO and government degree positions in enterprise growth and technique at biotech firms, together with BioArctic AB, Medivir AB and LifeCell Company. Christine additionally spent 10 years as an funding banker at Merrill Lynch in New York, the place she suggested biotech and pharmaceutical firms on licensing, M&A and financing. She most not too long ago served as Senior Vice President Company Growth at SSI Technique/NDA Group AB.
